Plasminogen activator inhibitor-1 and vitronectin promote vascular thrombosis in mice.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Blood

• Publication date

  2000-01-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/BLOOD.V95.2.577PMID 10627465
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Differential Role of Components of the Fibrinolytic System in the Formation and Removal of Thrombus Induced by Endothelial Injury

  1999cited by this paper
• A New Animal Model of Thrombophilia Confirms that High Plasma Factor VIII Levels Are Thrombogenic

  1999cited by this paper
• Vitronectin inhibits the thrombotic response to arterial injury in mice.

  1999cited by this paper
• Regulation of arterial thrombolysis by plasminogen activator inhibitor-1 in mice.

  1998cited by this paper
• Photochemically induced endothelial injury in the mouse as a screening model for inhibitors of vascular intimal thickening.

  1998cited by this paper
• Vascular wound healing and neointima formation induced by perivascular electric injury in mice.

  1997cited by this paper
• The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin.

  1996cited by this paper
• Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene.

  1996cited by this paper
• The serpin PAI-1 inhibits cell migration by blocking integrin αvβ3 binding to vitronectin

  1996cited by this paper
• Genetic analysis of the plasminogen and coagulation system in mice.

  1996cited by this paper
• Beneficial effect of CV-4151 (Isbogrel), a thromboxane A2 synthase inhibitor, in a rat middle cerebral artery thrombosis model.

  1995cited by this paper
• Peptide-mediated inactivation of recombinant and platelet plasminogen activator inhibitor-1 in vitro.

  1995cited by this paper
• Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effects of a plasminogen activator inhibitor type 1-neutralizing monoclonal antibody.

  1995cited by this paper
• Vitronectin is not essential for normal mammalian development and fertility.

  1995cited by this paper
• Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: insights from studies of vascular biology.

  1994cited by this paper
• Platelets inhibit fibrinolysis in vitro by both plasminogen activator inhibitor-1-dependent and -independent mechanisms.

  1994cited by this paper
• Stimulation of migration of human aortic smooth muscle cells by vitronectin: implications for atherosclerosis.

  1994cited by this paper
• Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization.

  1993cited by this paper
• Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis.

  1993cited by this paper
• Brief report: complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation.

  1992cited by this paper
• Arterial thrombosis model with photochemical reaction in guinea-pig and its property.

  1992cited by this paper
• Basic and clinical aspects of fibrinolysis and thrombolysis.

  1991cited by this paper
• Photochemically induced thrombosis model in rat femoral artery and evaluation of effects of heparin and tissue-type plasminogen activator with use of this model.

  1991cited by this paper
• A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type 1.

  1991cited by this paper
• [Type 1 plasminogen activator inhibitor].

  1990cited by this paper
• The Fibrinolytic Enzyme System and Its Role in the Etiology of Thromboembolic Disease

  1990cited by this paper
• Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor.

  1989cited by this paper
• Type 1 plasminogen activator inhibitor.

  1989cited by this paper
• Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin).

  1988cited by this paper
• Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction.

  1985cited by this paper

• Vitronectin in health and disease: Mechanisms and therapeutic implications

  2026cites this paper
• Hexokinase 2-mediated histone H3K18la promotes PAI-1-dependent thrombosis in acute myeloid leukemia via tumor-endothelial crosstalk

  2025cites this paper
• Improved micro-sampling methodology enables accurate platelet function analysis

  2025cites this paper
• Nanomedicine for venous thrombosis: Insights from an inflammatory perspective.

  2025cites this paper
• Protection of β2GPI-Deficient Mice from Thrombosis Reflects a Defect in PAR3-facilitated Platelet Activation.

  2025cites this paper
• PAI-1 interaction with sortilin-related receptor 1 is required for lung fibrosis

  2025cites this paper
• Correlation Between Oral Bacteria and Atherosclerotic Thrombotic Disease: Advances in Animal Model Studies

  2025cites this paper
• Targeting Fibrinolytic Inhibition for Venous Thromboembolism Treatment: Overview of an Emerging Therapeutic Approach.

  2024cites this paper
• Regulation of macrophage fibrinolysis during venous thrombus resolution.

  2024cites this paper
• Anti-hemostatic, antithrombotic, and chemical profiles of a curly-leaf variety of Petroselinum crispum (Apiaceae), a food and medicinal aromatic herb.

  2024cites this paper
• Surface Geometry of Cargo-less Gold Nanoparticles Is a Driving Force for Selective Targeting of Activated Neutrophils to Reduce Thrombosis in Antiphospholipid Syndrome

  2023cites this paper
• Peptides Derived from a Plant Protease Inhibitor of the Coagulation Contact System Decrease Arterial Thrombus Formation in a Murine Model, without Impairing Hemostatic Parameters

  2023cites this paper
• Identification of Genomic Loci Regulating Platelet Plasminogen Activator Inhibitor-1 in Mice.

  2023cites this paper
• Protection of β2GPI Deficient Mice from Thrombosis Reflects a Defect in PAR3-facilitated Platelet Activation

  2023cites this paper
• Vitronectin promotes immunothrombotic dysregulation in the venular microvasculature

  2023cites this paper
• Study on the Mechanism of NLRP3/IL-1/ NF-κB Signaling Pathway and Macrophage Polarization in the Occurrence and Development of VTE.

  2022cites this paper
• A targetable pathway in neutrophils mitigates both arterial and venous thrombosis

  2022cites this paper
• Fibrinolysis in Venous Thromboembolism

  2021cites this paper
• Pulmonary embolism — scattered elements of incomplete puzzle

  2021cites this paper
• A New Experimental Porcine Model of Venous Thromboembolism

  2021cites this paper
• Plasminogen activator inhibitor‐1: a potential etiological role in livedoid vasculopathy

  2020cites this paper
• Cardiovascular Research

  2020cites this paper
• By word of mouse: using animal models in venous thrombosis research

  2020cites this paper
• Translationale Forschung

  2019cites this paper
• Genome-wide association analysis of venous thromboembolism identifies new risk loci and genetic overlap with arterial vascular disease

  2019cites this paper
• Exploration of Unani concept of blood purifying drugs and likely models for its screening

  2019cites this paper
• Regulation of Fibrinolysis by Platelets

  2019cites this paper
• Vitronectin

  2019cites this paper
• Functional plasminogen activator inhibitor 1 is retained on the activated platelet membrane following platelet activation

  2019cites this paper
• In vivo monitoring of thrombosis in mice by optical coherence tomography

  2019cites this paper
• Phosphoproteomics of Acute Cell Stressors Targeting Exercise Signaling Networks Reveal Drug Interactions Regulating Protein Secretion.

  2019cites this paper
• Fibrinolysis and Inflammation in Venous Thrombus Resolution

  2019cites this paper
• Circulating miR-30c as a predictive biomarker of type 2 diabetes mellitus with coronary heart disease by regulating PAI-1/VN interactions.

  2019cites this paper
• Vitronectin from brain pericytes promotes adult forebrain neurogenesis by stimulating CNTF

  2019cites this paper
• Platelet Factor 4 and Von Willebrand Factor Form an Immunogenic, Prothrombotic Complex in Heparin-induced Thrombocytopenia

  2018cites this paper
• Plasminogen Activator Inhibitor-1 Promotes Neutrophil Infiltration and Tissue Injury on Ischemia–Reperfusion

  2018cites this paper
• Venous thrombosis models Photochemical injury

  2018cites this paper
• Plasminogen activator inhibitor-1: a risk factor for deep vein thrombosis after total hip arthroplasty

  2018cites this paper
• Dual-reporter high-throughput screen for small-molecule in vivo inhibitors of plasminogen activator inhibitor type-1 yields a clinical lead candidate

  2018cites this paper
• The Evolving Interplay among Abundant Adipokines in Patients with Hepatitis C during Viral Clearance

  2017cites this paper
• The antithrombotic and haemostatic effects of LASSBio‐752: a synthetic, orally active compound in an arterial and venous thrombosis model in rats

  2017cites this paper
• A long-acting PAI-1 inhibitor reduces thrombus formation

  2017cites this paper
• Selection of animal model in fibrinolysis , a challenge

  2017cites this paper
• Mutation of the Kunitz-type proteinase inhibitor domain in the amyloid β-protein precursor abolishes its anti-thrombotic properties in vivo.

  2017cites this paper
• Improved anticoagulant effect of fucosylated chondroitin sulfate orally administered as gastroresistant tablets

  2017cites this paper
• Hematopoietic Deficiency of miR-223 Attenuates Thrombosis in Response to Photochemical Injury in Mice

  2017cites this paper
• Platelet‐Derived Factor V Is a Critical Mediator of Arterial Thrombosis

  2017cites this paper
• Animal models of venous thrombosis.

  2017cites this paper
• Mouse models of deep vein thrombosis

  2016cites this paper
• Anticoagulant and antithrombotic activities of low-molecular-weight propylene glycol alginate sodium sulfate (PSS).

  2016cites this paper
• Platelets Proteomic Profiles of Acute Ischemic Stroke Patients

  2016cites this paper
• Significant Improvement of Antithrombotic Responses to Clopidogrel by Use of a Novel Conjugate as Revealed in an Arterial Model of Thrombosis

  2016cites this paper
• Murine Models of Thrombosis and Hemostasis

  2016cites this paper
• Adipose Tissue-Derived Plasminogen Activator Inhibitor-1 Function and Regulation.

  2016cites this paper
• Reduced Perinatal Leptin Availability May Contribute to Adverse Metabolic Programming in a Rat Model of Uteroplacental Insufficiency.

  2016cites this paper
• Animal Models of Thrombosis From Zebrafish to Nonhuman Primates: Use in the Elucidation of New Pathologic Pathways and the Development of Antithrombotic Drugs.

  2016cites this paper
• Intérêt de la vectorisation du t-PA au thrombus : exemple du Fucoidan aminé

  2016cites this paper
• Genetic Models of Hemostasis and Thrombosis

  2015cites this paper
• Plasminogen activator inhibitor‐1 is independently associated with non‐alcoholic fatty liver disease whereas leptin and adiponectin vary between genders

  2015cites this paper
• Murine arterial thrombus induction mechanism influences subsequent thrombodynamics.

  2015cites this paper
• Evaluating PAI-1 as a biomarker for stress in diving: human serum total PAI-1 is unaltered after 2 h dry exposures to 280 kPa hyperbaric air

  2015cites this paper
• Thrombus formation induced by laser in a mouse model

  2014cites this paper
• Comparative Fibrinolysis

  2014cites this paper
• Mausmodelle der tiefen Venenthrombose

  2014cites this paper
• Mouse models of deep vein thrombosis

  2014cites this paper
• Enhanced venous thrombus resolution in plasminogen activator inhibitor type‐2 deficient mice

  2014cites this paper
• Plasminogen activator‐1 overexpression decreases experimental postthrombotic vein wall fibrosis by a non‐vitronectin‐dependent mechanism

  2014cites this paper
• How to analyze the anticoagulant and antithrombotic mechanisms of action in fucanome and galactanome?

  2014cites this paper
• Effect of exogenous leptin on thrombotic and metabolic profiles of FVB/B6 lipodystrophic mice

  2013cites this paper
• The Role of Platelets in Fibrinolysis

  2013cites this paper
• Blood Constituents and Safety Pharmacology 11

  2013cites this paper
• Three Decades of Research on Plasminogen Activator Inhibitor-1: A Multifaceted Serpin

  2013cites this paper
• The cellular microenvironment modulates the role of PAI-1 and vitronectin in mediating cell-matrix interactions

  2013cites this paper
• α(1,3)-Fucosyltransferases FUT4 and FUT7 control murine susceptibility to thrombosis.

  2013cites this paper
• Paradoxical protection from atherosclerosis and thrombosis in a mouse model of sickle cell disease

  2013cites this paper
• Promoter variants of VTN are associated with vascular disease.

  2013cites this paper
• 1 integrin to vascular thrombosis in vivo β 2 α The contributions of the

  2013cites this paper
• are highly potent thrombogenic site-directed anticoagulants Fusion proteins comprising annexin V and Kunitz protease inhibitors

  2013cites this paper
• Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo

  2012cites this paper
• Critical review of mouse models of venous thrombosis.

  2012cites this paper
• In vivo monitoring of venous thrombosis in mice

  2012cites this paper
• Type I interferons modulate vascular function, repair, thrombosis, and plaque progression in murine models of lupus and atherosclerosis.

  2012cites this paper
• Die Rolle von Leukozyten in der Entstehung der venösen Thrombose - in vivo Untersuchungen im Mausmodell

  2012cites this paper
• Rolle der Neutrophil Extracellular Traps (NETs) bei der Entstehung der venösen Thrombose

  2012cites this paper
• Recent Insights into the Molecular and Cellular Contributions to Venous Thrombosis

  2012cites this paper
• Effect of the factor Xa inhibitor rivaroxaban on arterial thrombosis in wild-type and apolipoprotein E-deficient mice.

  2012cites this paper
• The hyperfibrinolytic state of mice with combined thrombin‐activatable fibrinolysis inhibitor (TAFI) and plasminogen activator inhibitor‐1 gene deficiency is critically dependent on TAFI deficiency

  2012cites this paper
• Vitronectin in Vascular Context: Facets of a Multitalented Matricellular Protein

  2011cites this paper
• COX‐1+/−COX‐2−/− genotype in mice is associated with shortened time to carotid artery occlusion through increased PAI‐1

  2011cites this paper
• Effects of air pollution on vascular thrombosis

  2011cites this paper
• Type I Interferons and the Development of Impaired Vascular Function and Repair in Human and Murine Lupus

  2011cites this paper
• Electrolytic Inferior Vena Cava Model (EIM) of Venous Thrombosis

  2011cites this paper
• The hemostatic system as a modulator of atherosclerosis.

  2011cites this paper
• Overexpression of the Cell Cycle Inhibitor p16INK4a Promotes a Prothrombotic Phenotype Following Vascular Injury in Mice

  2011cites this paper
• Use of mouse models to study plasminogen activator inhibitor-1.

  2011cites this paper
• Adipokines and thrombosis

  2011cites this paper
• Monocyte-bound PF4 in the pathogenesis of heparin-induced thrombocytopenia.

  2010cites this paper
• Resident Endothelial Cells Surrounding Damaged Arterial Endothelium Reendothelialize the Lesion

  2010cites this paper
• In vivo models for the evaluation of antithrombotics and thrombolytics.

  2010cites this paper
• Thrombogenesis with continuous blood flow in the inferior vena cava

  2010cites this paper